This post was originally published on this site Personalized treatment intensity is crucial to the success of less toxic and demanding therapies for women with HER2-positive breast cancer, according to a spokesperson from the European Society for Medical Oncology (ESMO). The remarks by Carmen Criscitiello, MD, PhD, accompanied updated results from the PERNETTA trial (EudraCT…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
FDA Won’t Ban Sales of Breast Implants Linked to Lymphoma, But Considers Black Box Warning
This post was originally published on this site In announcing that breast implants linked to anaplastic large-cell lymphoma (ALCL) can continue to be sold in the United States, the U.S. Food and Drug Administration (FDA) proposed assurances that the potential risks of such implants are better known. In its recent statement, the agency said it would…
Ampligen Showing Promise for Recurrent Ovarian Cancer in Phase 1/2 Trial, Phase 2 Study Now Recruiting
This post was originally published on this site Hemispherx Biopharma‘s experimental therapy Ampligen (rintatolimod) can change the tumor microenvironment to increase the amount of infiltrating T-cells, an approach that is showing promise in a Phase 1/2 clinical trial for recurrent ovarian cancer, according to the company. Funded in part by an Ovarian Cancer Specialized Program…
Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA
This post was originally published on this site Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have failed at least four prior lines of therapy, the company announced. The designation is intended to speed the therapy’s development and…
Young Women More Likely to Face Aggressive BC Types, But Proper Treatment Improves Outcomes
This post was originally published on this site Young women are more likely than older ones to be diagnosed with more aggressive forms of breast cancer, but their outcomes can be good if they follow recommended treatments. That is the take-home messages of two studies presented at the recent ESMO Breast Cancer Congress 2019, held…
Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
This post was originally published on this site The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (bortezomib) and dexamethasone, for the treatment of some adult patients with multiple myeloma. Revlimid, combined with Velcade and dexamethasone (RVd), is now indicated for the treatment of newly diagnosed, untreated adults…
FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venclexta is a potent selective inhibitor of the B-cell lymphoma-2 (BCL-2)…
First Patients Dosed in iTeos’ Experimental A2A Receptor Antagonist Trial for Solid Tumors
This post was originally published on this site iTeos Therapeutics’ Phase 1/1b clinical trial testing its experimental A2A receptor antagonist, EOS100850, has dosed the first group of patients with advanced solid tumors, the company announced. “I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with…
Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests
This post was originally published on this site Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were presented at the American Urological Association’s 2019 Annual Meeting, May 3-6, in Chicago, in the study, “Survival…
Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program
This post was originally published on this site Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called My Mentor Connections, the program enlists caregivers and patients as mentors who volunteer to provide answers and support over the phone to other patients or…
Rare Diseases Constitute a ‘Public Health Issue,’ NCATS Director Warns
This post was originally published on this site With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS)…
Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows
This post was originally published on this site Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial shows. Trastuzumab deruxtecan is a combination of the anti-cancer HER2-targeting antibody trastuzumab (marketed under the brand name Herceptin), and an…